fucose and refludan

fucose has been researched along with refludan in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bologna, L; Da Roit, F; Ferrara, C; Golay, J; Introna, M; Klein, C; Leusen, JH; Rambaldi, A	1

Other Studies

1 other study(ies) available for fucose and refludan

Article	Year
Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. Blood, 2013, Nov-14, Volume: 122, Issue:20 Topics: Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibody Affinity; Antigens, CD20; CD11b Antigen; Fucose; Glycosylation; GPI-Linked Proteins; Hirudins; Humans; Interleukin-6; Interleukin-8; L-Selectin; Leukemia, Lymphocytic, Chronic, B-Cell; Neutrophil Activation; Phagocytosis; Protein Engineering; Protein Isoforms; Receptors, IgG; Recombinant Proteins; Rituximab; Surface Plasmon Resonance; Tumor Necrosis Factor-alpha; Up-Regulation	2013

Article

Year

Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab.

Blood, 2013, Nov-14, Volume: 122, Issue:20

Topics: Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibody Affinity; Antigens, CD20; CD11b Antigen; Fucose; Glycosylation; GPI-Linked Proteins; Hirudins; Humans; Interleukin-6; Interleukin-8; L-Selectin; Leukemia, Lymphocytic, Chronic, B-Cell; Neutrophil Activation; Phagocytosis; Protein Engineering; Protein Isoforms; Receptors, IgG; Recombinant Proteins; Rituximab; Surface Plasmon Resonance; Tumor Necrosis Factor-alpha; Up-Regulation

2013